Medicortex Finland Oy Announces the Advancement in Clinical Trial for Detection of Mild Traumatic Brain Injury in Children
TURKU, Finland. Medicortex Finland Oy announces achievement of the halfway in the clinical trial for detection of mild traumatic brain injury (TBI) and concussion in children and adolescents. Company's third clinical trial is being conducted at Satasairaala hospital in Finland. About 50% of the target number of head injury patients and healthy controls have already been enrolled in the study which started in March this year.
Medicortex Finland Oy on saavuttanut puolivälin lasten ja nuorten tapaturmaisten aivovammojen diagnostiikkaan liittyvässä kliinisessä tutkimuksessa. Yrityksen kolmas kliininen tutkimus toteutetaan Satasairaalassa Porissa. Tavoitemäärään nähden noin 50% aivotärähdyspotilaista ja terveistä verrokeista on jo saatu tämän vuoden maaliskuussa alkaneeseen tutkimukseen.
The onset of the corona pandemic somewhat retarded the rate of patient enrolment in the early phase of the study as the hospital was put on standby to nurse infected patients, and the number of eligible head injury patients went down because of suspension of several everyday goings and leisure activities. Since the late spring the situation has gradually normalized and we are receiving near regular number of patients in the hospital and enrolling patients at a steady rate in the study, said Dr. Sari Malmi, the Principal Investigator of the study and the Head of Pediatric Surgery Department.
“A diagnostic kit for rapid detection of mild TBI in children is important. It will satisfy the pressing need to improve the detection of brain injury in children who suffered a head injury” said Dr. Mårten Kvist, Medical Director of Medicortex Finland Oy. The rapid diagnostic kit ProbTBI, currently being developed by Medicortex, will help to diagnose brain injury especially in patients who do not show visible symptoms of brain damage which is frequently the case in concussion and mild injury.
Satasairaala hospital in Pori is the main hospital in Satakunta province with the first level pediatric emergency department and expertise in the TBI management. Body fluid samples are being collected from 30 young patients (0 - 17 years) with suspected mild TBI and from 30 age-matched healthy volunteers. The samples will be studied with respect to a specific biomarker signature following a head injury.
"ProbTBI™ will be a highly innovative diagnostic kit for rapid detection of concussion. Children in particular will benefit from it since they can be refrained from radiation or sedation which are needed for the CT scan of the head, as well as from an exposure to other sick patients in the hospital "said Dr. Adrian Harel, CEO of Medicortex. “Participation of the young patients shortly after a head injury is a challenge, but we have a committed and skilled clinical team working with us in the hospital” Dr. Harel adds.
In this clinical trial, Medicortex intends to collect a sufficient number of pediatric samples in order to test the applicability of the brain injury test in children, an expected continuation for previously proven clinical performance in adults. The clinical trial is posted at the public database ClinicalTrials.gov with identifierNCT04288167.
Medicortex Finland Oy is engaged in the development of a first-of-its-kind diagnostic kit for rapid detection of concussion and mild TBI from non-invasive body fluid samples. The Company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. The patent portfolio held by Medicortex secures exclusivity to develop the product. More information about TBI and its detection is available on the Company's website at www.medicortex.fi
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
About Medicortex Finland Oy
Itäinen Pitkäkatu 4 B
Medicortex Finland Oy (www.medicortex.fi) on tutkimuslähtöinen lääkealan yritys, joka kehittää uudenlaista diagnostista menetelmää perustuen biomerkkiaineisiin.
Subscribe to releases from Medicortex Finland Oy
Subscribe to all the latest releases from Medicortex Finland Oy by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Medicortex Finland Oy
New key persons joining Medicortex Finland18.1.2022 10:37:11 EET | Press release
Turku, Finland. Medicortex Finland Oy, a Turku based biotechnology company developing breakthrough biomarker diagnostics for brain injury detection, announces election of Anna Tenstam as a new member of company’s board of directors, as well as appointment of Mikko Laurila as Chief Financial Officer (CFO) of the company.
Medicortex Finland Oy Announces Issuance of a Patent in Israel9.12.2021 11:14:02 EET | Press release
TURKU, Finland. Medicortex Finland Oy, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), announces approval of company’s pivotal patent in Israel.
Medicortex Finland Oy Announces Issuance of a Patent in Canada3.8.2021 08:25:25 EEST | Press release
TURKU, Finland. Medicortex Finland Oy, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that company’s core patent covering the diagnostic kit and innovative biomarker was granted in Canada.
Business Finland myönsi rahoitusta Medicortexille4.3.2021 14:58:53 EET | Tiedote
Medicortex Finland Oy, turkulainen aivovammojen diagnostiikkaan ja lääkekehitykseen erikoistunut yritys, on saanut rahoitusta Business Finlandilta. Rahoituksen avulla yritys voi nopeuttaa tapaturmaisten aivovamman ja aivotärähdyksen havaitsemiseen käytettävän pikatestin kehitystä.
Medicortex Finland Oy Announces Issuance of a Patent in the United States18.9.2020 09:44:43 EEST | Press release
TURKU, Finland. Medicortex Finland Oy, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering company’s diagnostic kit and innovative brain injury biomarker.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom